MARKET

SYNH

SYNH

Syneos Health
NASDAQ
51.45
+2.21
+4.49%
Closed 16:07 10/04 EDT
OPEN
50.23
PREV CLOSE
49.24
HIGH
51.83
LOW
50.20
VOLUME
750.39K
TURNOVER
--
52 WEEK HIGH
104.18
52 WEEK LOW
46.24
MARKET CAP
5.28B
P/E (TTM)
19.29
1D
5D
1M
3M
1Y
5Y
Citigroup Maintains Neutral on Syneos Health, Lowers Price Target to $55
Citigroup analyst Patrick Donnelly maintains Syneos Health (NASDAQ:SYNH) with a Neutral and lowers the price target from $70 to $55.
Benzinga · 1h ago
--Citigroup Adjusts Syneos Health's Price Target to $55 From $70, Maintains Neutral Rating
--Citigroup Adjusts Syneos Health's Price Target to $55 From $70, Maintains Neutral Rating
MT Newswires · 5h ago
Baird Maintains Outperform on Syneos Health, Lowers Price Target to $80
Baird analyst Eric Coldwell maintains Syneos Health (NASDAQ:SYNH) with a Outperform and lowers the price target from $89 to $80.
Benzinga · 09/16 12:07
Baird Adjusts Syneos Health's Price Target to $80 From $89, Keeps Outperform Rating
Baird Adjusts Syneos Health's Price Target to $80 From $89, Keeps Outperform Rating
MT Newswires · 09/16 08:36
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $4.26.
Benzinga · 09/14 14:07
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.
Benzinga · 09/14 09:54
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Benzinga · 09/14 07:58
Guggenheim Downgrades Syneos Health to Neutral From Buy
Guggenheim Downgrades Syneos Health to Neutral From Buy
MT Newswires · 09/14 05:58
More
About SYNH
Syneos Health, Inc. is a biopharmaceutical solutions company. It provides a range of clinical and commercial services to customers in the pharmaceutical, biotechnology, and healthcare industries. It offers both stand-alone and integrated biopharmaceutical product development solutions ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. It operates through two business segments: Clinical Solutions and Commercial Solutions. Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communication solutions, and consulting services.

Webull offers kinds of Syneos Health Inc stock information, including NASDAQ:SYNH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYNH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYNH stock methods without spending real money on the virtual paper trading platform.